Learn more about the importance of ensuring and maintaining the quality of your CT machine as well as protecting your accreditation.
Legalities in health care can often make the practice of radiology muddled at best—especially for facilities using Picture Archiving Communication Systems (PACS). In the second of a two-part series, Eliot Siegel, MD, RadSite’s Chief Technology Officer, discusses whether to retain the markings produced by mammography computer-aided detection (CAD) software to highlight suspicious findings, which could have important medicolegal implications.
Ensuring a patient’s exposure to ionizing radiation is “As Low As Reasonably Achievable” (ALARA) while providing the highest quality diagnostic image requires a delicate balance and is the focus of radiation protection programs nationwide. RadSite’s safety initiatives include a review of radiation safety policies and procedures as well as ensuring that radiation safety educational programs are in place.
It is no secret that quality of care is a hot topic in health, and medical imaging is no exception. The Medicare Improvements for Patients and Providers Act (MIPPA) of 2008 requires all providers who bill the Centers for Medicare and Medicaid Services (CMS) for advanced diagnostic imaging (ADI) services under Part B of the Medicare Physician Fee Schedule to be accredited in order to receive reimbursements. These services include CT, MRI, PET and SPECT. RadSite is one of four programs approved by CMS to offer ADI accreditation. If your current MIPPA accreditation is expiring, and you want a user-friendly, affordable accreditation program, consider RadSite’s MIPPA Accreditation Program (MAP).
A recent study published in JAMA Neurology explores the effect of elevated amyloid levels on subsequent changes in cognition and biomarkers. The findings indicate that in normal people, elevated levels of amyloid can signal cognitive decline. While the authors are not suggesting that these findings should impact current clinical recommendations, the conclusions could impact clinical trials for testing amyloid levels.